Partnering with Carrick Therapeutics


Carrick Therapeutics is building an innovative portfolio of first-in-class treatments that target multiple mechanisms of the most aggressive forms of cancer and are optimized to a patient’s individual tumour through identification of predictive biomarkers.

What we’re seeking

We are actively seeking new partners with compounds that target the key pathways in cancer progression and adaptive resistance, so if you would like to explore partnering opportunities with us and understand how our team of leading experts could help advance your asset, please contact

Why partner with Carrick Therapeutics?

Proven Expertise

Carrick Therapeutics is founded on the highly-experienced team we have brought together, scientific, clinical and commercial, with a proven track record of identifying and developing commercially-successful innovative medicines.

Our team includes leading oncology researchers from institutions at Cambridge, London, Oxford and Edinburgh working in close collaboration with the world-renowned Cancer Research UK’s network of research centres.

Institute of Cancer Research
University of Oxford
University of Cambridge
Imperial College London
University of Edinburgh

External Collaborators

We have also established an outsourced partnership business model that provides us with access to expertise across key areas including biomarkers, preclinical, manufacturing, clinical and patient stratification.

WuXi AppTec
Oncotest CRL

Financial Backing

Carrick Therapeutics was launched on the back of a $95m funding round led by a group of healthcare investors, including ARCH Venture Partners & Rosetta Capital, with outstanding records of success in accelerating the development of cutting-edge science into new therapies.

By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.